Introduction
The intestine is the most proliferative tissue in the body, as the epithelial layer of the small intestine renews itself every 3-5 days. Intestinal stem cells (ISCs) in the base of intestinal crypts tightly control this process by producing intestinal progenitors known as transit amplifying (TA) cells, which are located above the stem cells in the crypt. These progenitor cells proliferate and differentiate into all absorptive and secretary cells. Multiple pathways including NOTCH, MAPK, WNT, HIPPO, and BMP signaling coordinate orderly proliferation and differentiation to maintain continuous production of the diverse cell types of the intestinal epithelium. Among these regulatory pathways, Wnt/β-catenin signaling plays a pivotal role to maintain intestinal stem pools. Targeting Wnt signaling by diverse means including overexpression of DKK1 (1), inhibition of RSPOs (2, 3), knockout of TCF4 or β-catenin in the epithelial cells, or inhibition of PORCN in the stroma impairs the function of small ISCs and blocks proliferation following 5-7 days of treatment (4) (5) (6) (7) . It is therefore widely held that Wnt signaling facilitates both stemness and proliferation. However, establishing the direct role of Wnts is challenging in a system with multiple interacting components. In fact, other signaling pathways such as MAPK (8) (9) (10) and even PDG2 (11) also impact the proliferation of intestinal stem and progenitor cells. Wnt signaling might interact with these additional pathways in a direct or indirect manner. It is difficult to tease out dependencies and causality in single time point, long-term assays. Indeed, little is known about the immediate effect of Wnt inhibition on ISC proliferation or the TA cells, even though this is likely to be the critical time point for the subsequent collapse of the ISC compartment.
Here, we used a PORCN inhibitor (6, 12) to acutely inhibit secretion of all Wnts and test the role of Wnts in ISC proliferation. Our results show that Wnt signaling suppresses both proliferation and MAPK signaling in ISCs. This serves to maintain stem cell pools by preventing their differentiation into TA cells. These results clarify the role of Wnt signaling in the intestine. Combination therapy with Wnt and MEK inhibitors might provide added efficacy in select Wnt-addicted cancers.
Results and Discussion
To examine the early effects of withdrawal of Wnt signaling in ISC proliferation, we selected a dose of the PORCN inhibitor C59 that impaired intestinal homeostasis within 10-15 days (6). C57/ BL6 mice were administered a single dose of C59 (100 mg/kg) or vehicle as control by oral gavage and sacrificed 24 hours later. Proliferating intestinal cells were assessed using EdU incorporation. As expected, EdU incorporation was seen primarily in TA cells of vehicle-treated mice ( Figure 1A and Supplemental Figure 1C ; supplemental material available online with this article; https:// doi.org/10.1172/JCI99325DS1). Unexpectedly, we observed a significant increase in proliferating cells in crypt base cells in the duodenum, jejunum, and ileum in C59-treated mice ( Figure 1A , Supplemental Figure 1A , and quantified in Figure 1B ). To independently validate this finding, intestinal samples from these mice
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In pilot studies, labeling was evaluated 24 hours after tamoxifen administration. Occasional crypts contained single cells that were positive for Rosa-tdTomato, but not for Lgr5-EGFP, indicating that TA cells can emerge from Lgr5 + cells within this time frame (Supplemental Figure 3A) . To avoid potential lineage tracing from newly generated TA cells, we administered the first dose of C59 12 hours after the tamoxifen and then continued daily C59 (100 mg/kg) treatment for 3 days (Figure 2A ). These lineage-tracing experiments did not show any difference between C59-and were stained for Ki67. Similar to what was seen with EdU, the fraction of crypt base cells positive for Ki67 increased upon C59 treatment. (Figure 1 , C and D, and Supplemental Figure 1D ).
The observed proliferation in the stem cell compartment at the base of the crypt in response to C59 could be generated by different biological mechanisms. One trivial explanation is that PORCN inhibition is proapoptotic for ISCs and thus TA cells simply moved down toward the base of the crypt. To test this possibility, intestinal samples were stained with antibodies against cleaved-caspase 3 (CAS3). As shown in Figure 1E and Supplemental Figure 1E This proliferation phenotype could be a product of ISC differentiation. Thus, we performed lineage tracing to determine the fate of ISC cells after Wnt inhibition. Wnt-dependent Lgr5 expression marks ISCs, which normally divide symmetrically to dose of 100 mg/kg (50 mg/kg twice daily) as this high dose was previously shown to impair intestinal homeostasis within 5-7 days. A substantial increase in the number of proliferative cells was seen on the first 2 days of C59 treatment, and this was followed by the disappearance of proliferative cells by the fourth day (Supplemental Figure 2 , A-C). Interestingly, we observed normal lineage tracing in the crypts of the C59-treated mice ( Figure 2 , C and D, and Supplemental Figure 3C ). These findings support the conclusion that acute Wnt inhibition leads to enhanced ISC proliferation and unimpaired differentiation. Figure 3C ).
The dosing schedule of C59 can have a time-dependent impact on Wnt activity in vivo. The in vivo half-life of C59 is approximately 2 hours (12), and consistent with previous reports with other PORCN inhibitors (15, 16) , there was a rebound of Wnt target gene expression 1 day after the first dose of C59 (see Supplemental Figure 4A ). If the proliferative burst in Lgr5 + cells is due to drug washout, the proliferative effect might be blunted by more frequent dosing. Conversely, if the suppression of Wnt signaling causes the increase in proliferation of Lgr5 + cells, more frequent dosing would enhance the proliferation rate. Therefore, the experiment was repeated with mice dosed twice daily for a total daily ed mice. There was a significant reduction in the expression of Axin2 (Wnt target) and the stem cell markers Lgr5, Olfm4, Ascl2, Hopx, and Bmi1 in the C59-treated mice as early as 1 day after the first dose (Figure 3A) . Conversely, expression of intestinal differentiation markers was not affected during the course of this experiment (Supplemental Figure 4C ). In addition, EdU staining in C59-treated Lgr5-EGFPCreERT2/Rosa-LSL-tdTomato mice revealed loss of EGFP expression (Supplemental Figure 4B ). Taken together, this suggests that inhibiting Wnt signaling with C59 disturbs ISC self-renewal, but not ISC differentiation into TA cells. In agreement, a similar passive lineage commitment of ISCs into TA cells by in vivo targeting of both RSPO and Wnt receptors was recently reported (2). We considered how Wnt inhibition might drive proliferation. Several lines of evidence suggested the involvement of the MAPK pathway. First, EGFR inhibition, which blocks regenerate the intestinal epithelial cells after severe damage (Supplemental Figure 3B ) (19, 20) . To test if Bmi1 + ISCs could account for the crypt cell proliferation after acute Wnt inhibition, Bmi1-CreER T2 /Rosa-LSL-tdTomato mice were treated with tamoxifen and then either C59 or vehicle according to the time line indicated in Supplemental Figure 3D . Under unstressed conditions, more tdTomato + cells appeared in the crypt base 3 days after tamoxifen injection. However, the C59-treated mice had significantly fewer labeled cells in the crypt base of the jejunum and ileum (Supplemental Figure 3, E and F) . Thus, the proliferation in the crypt base after acute Wnt inhibition does not appear to be due to active regeneration by Bmi1 + ISC cells. To examine the effect of PORCN inhibition on Wnt signaling, we determined the level of mRNA expression for Wnt target genes and stem cell markers by quantitative RT-PCR in vehicle-and C59-treat- Figure 4A .
In contrast to what was observed with C59 treatment alone, the combination of trametinib and C59 led to a rapid decline in the health of the treated mice, as evidenced by decreased activity, rapid weight loss, and ascites. IHC with p-ERK1/2 antibody confirmed that trametinib reduced MAPK signaling (Supplemental Figure 5C ). The combination of trametinib and C59 was not toxic for ISCs as there was no staining for the apoptotic marker CAS3 in crypt bases (Supplemental Figure 5D ). In agreement, total proliferation as judged by counts of EdU + cells was significantly reduced in the trametinib plus C59 group as compared with the vehicle or C59 groups ( Supplemental Figure 5A) . Interestingly, trametinib alone increased baseline EdU uptake at the base of the crypt, which we suspect was secondary to enteropathy in the villi (25) (Figure 4, A-D) . Nevertheless, ISC proliferation in mice from the trametinib plus C59 group was similar to trametinib treatment alone and significantly low-MEK-ERK signaling, was recently shown to suppress proliferation in intestinal organoid cultures (8) . Second, high levels of p-ERK1/2, a measure of MAPK signaling, were reported in TA cells (21) . Third, RSPO3, a Wnt sensitizer, was shown to inhibit MAPK signaling and block osteogenic differentiation of adipocyte stem cells in culture (22, 23) . Therefore, the intestinal samples of C59-or vehicle-treated mice were stained for p-ERK1/2 by immunohistochemistry (IHC). The p-ERK1/2 staining was mainly positive in TA cells in vehicle-treated mice ( Figure 3B ). However, p-ERK1/2 expression was significantly increased in crypt base cells intercalated between Paneth cells in C59-treated mice (Figure 3 , B and C and Supplemental Figure 4D ). Thus, Wnt inhibition-induced ISC proliferation is associated with increased MAPK signaling.
To experimentally evaluate the role of MAPK signaling in intestinal proliferation following Wnt inhibition, mice were treated with trametinib (24), a potent MEK inhibitor, prior to poration using EdU and ClickiT EdU Alexa Fluor 488 and 647 Imaging Kits from Life Technologies (catalog E10187, C10337, and C10640 respectively) as previously described (6) . All samples were analyzed using a Leica SP5 inverted confocal microscope.
Images for different parts of the intestine were obtained based on the aforementioned criteria for tissue preparation and antibody staining. Quantification of EdU + cells was done blindly on 10 cells in the bottom of the crypt based on cell position 0, as shown by Supplemental Figure 1C . We defined TA cells based on position within the crypt, EdU incorporation, and expression of cell cycle markers. Statistics. Data were analyzed using Prism 6 software (GraphPad Software).
Study approval. The Duke University IACUC (Durham, NC) approved all animal studies.
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er than C59-treated mice. Taken together, these findings suggest that MEK inhibition suppresses the proliferation caused by acute Wnt inhibition (Figure 4, C and D) . This effect was seen throughout the majority of the small intestine with the exception of small parts of the proximal and distal small intestine (Supplemental Figure 1B and Supplemental Figure 5B ). Admittedly, other signaling mechanisms might coexist with ERK1/2 activation, and/or compensate for ERK inhibition, for example, activation of ERK5 (25) . With this caveat acknowledged, inhibition of MEK prior to Wnt inhibition blocked proliferation and differentiation of ISCs into TA cells and impaired intestinal homeostasis shortly after C59 administration. This model is consistent with studies showing that increased MAPK signaling in the intestine due to BRAFV600 mutation promotes loss of ISCs and increases differentiation (26, 27) .
Taken together, our data not only demonstrate an unanticipated role of Wnt suppressing ISC proliferation, but also supports an interaction between Wnt and MAPK signaling in vivo. We propose that Wnt signaling maintains quiescent ISC pools through suppression of the MAPK pathway in the intestine. These concepts will be useful in designing combination therapies for cancer and in regenerative medicine. (+,-)/Rosa-LSL-tdTomato(+,-) mice respectively. PORCN inhibitor C59 was synthesized by the Duke University Small Molecule Synthesis facility and administered as described (28) . Trametinib was purchased from Chemitek (catalog CT-GSK212) and dissolved in DMSO (10 mg/ml). The trametinib stock was adjusted to a final concentration of 0.3 mg/ml using vehicle solution (0.5% methylcellulose plus 0.2% Tween-80) and administered at 3 mg/kg dose by oral gavage.
Methods

Mice strains and drug administration. Lgr5-EGFP-
Cell proliferation assay. Cell proliferation in vivo was measured by administering EdU 2 hours prior to euthanasia and measuring incor-
